1. Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of βIII‐Tubulin Expression as a Predictive Marker. (12th July 2013) Authors: Saura, Cristina; Tseng, Ling‐Ming; Chan, Stephen; Chacko, Raju T.; Campone, Mario; Manikhas, Alexy; Nag, Shona M.; Leichman, Cynthia G.; Dasappa, Lokanatha; Fasching, Peter A.; Hurtado de Mendoza, Fernando; Symmans, W. Fraser; Liu, David; Mukhopadhyay, Pralay; Horak, Christine; Xing, Guan; Puszta... Journal: Oncologist Issue: Volume 18:Number 7(2013) Page Start: 787 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. Issue 14 (6th December 2019) Authors: Candelaria, Myrna; González, Derlis E.; Delamain, Marcia Torresan; Bär, Daniel Oscar; Beniwal, Surender Kumar; Dasappa, Lokanatha; Flores, David Hugo; Querol, John; Guan, Toh See; Lipatov, Oleg Nikolaevich; Volodicheva, Elena Mikhailovna; Patel, Moosa; Safaee Nodehi, Sayyed Reza; Fogliatto, Laura... Journal: Leukemia & lymphoma Issue: Volume 60:Issue 14(2019) Page Start: 3375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. (September 2019) Authors: Huober, Jens; Holmes, Eileen; Baselga, José; de Azambuja, Evandro; Untch, Michael; Fumagalli, Debora; Sarp, Severine; Lang, Istvan; Smith, Ian; Boyle, Frances; Xu, Binghe; Lecocq, Christophe; Wildiers, Hans; Jouannaud, Christelle; Hackman, John; Dasappa, Lokanatha; Ciruelos, Eva; Toral Pena, Juan... Journal: European journal of cancer Issue: Volume 118(2019) Page Start: 169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗